Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After Nephrectomy

New England Journal of Medicine - United States
doi 10.1056/nejmoa1611406
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Massachusetts Medical Society

Related search

Adjuvant Therapy After Nephrectomy for Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2018English

Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Clinical Cancer Research
Cancer ResearchOncology
2018English

The Current State of Adjuvant Therapy Following Surgery for High-Risk Renal Cell Carcinoma

European Urology Focus
Urology
2019English

Pancreatic Metastasis of Renal Cell Carcinoma Occurring 17 Years After Nephrectomy

The journal of the Japanese Practical Surgeon Society
1991English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

The Lancet
Medicine
2016English

Sunitinib Causes Macrocytosis in Patients With Advanced Renal Cell Carcinoma

Current Oncology
Oncology
2010English

A Case of Endobronchial Metastasis From Renal Cell Carcinoma 7 Years After Nephrectomy

Tuberculosis and Respiratory Diseases
PulmonaryInfectious DiseasesRespiratory Medicine
2006English

A Rare Case of Sunitinib-Induced Rhabdomyolysis in Renal Cell Carcinoma

Case Reports in Oncological Medicine
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy